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were assigned a score. Scores relevant to each individual patient
were totaled and this equated to an acuity level. Validation and
reliability testing were performed and the tool piloted for 4 weeks
in 6 different units. All units were Haematology/SCT (adult and
pediatric) but may also have included Oncology. Analysis of the
results shows that 86% of the nurses using the tool believed that
the acuity of their patient was accurately reﬂected. Of those who
didn’t agree with the tool’s rating, all believed that the acuity level
should have been higher, particularly those patients whose condi-
tion was unstable and whose acuity rating was on the border line
between levels. Compliance in units that did not receive face-to-
face orientation was lower.
A major limitation of the study was an unrealistic timeframe
which impacted on validity and reliability testing and compliance.
More extensive trialing of a reﬁned tool is planned. The develop-
ment of this tool provides a sound tool on which to build, whilst
succinctly demonstrating the difﬁculties in accurately assessing the
acuity of SCT/Haematology patients.
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DEVELOPING THE CRITICAL THINKING SKILLS OF NOVICE NURSES IN
BLOOD AND MARROW TRANSPLANTATION
Mishaw, K. University of Texas, Houston, TX.
Today’s nursing shortage is evidenced by fewer nurses entering
the workforce, acute nursing shortages in certain geographic areas,
and a shortage of nurses prepared to meet specialty patient needs
in a changing health care environment. This is clearly evident in
the blood and marrow transplant unit at MDACC, which processes
approximately 500 transplants per year. It is a challenge to recruit
nurses with cancer experience, much less, with a background in this
specialty. Nurses new to the blood and marrow transplant arena are
challenged with complex information including hematology, im-
munology as well as acute and chronic complications of the trans-
plant treatment modality. This BMT unit reﬁned its current ori-
entation program to include evidence-based practice and
implemented strategies for critical thinking skills. Methods were
developed and implemented to train the nurse coaches to teach
critical thinking skills. Tools were developed for use by both the
coach and new nurse to promote critical thinking. Tools developed
include orientation pathways with transplant modules, communi-
cation tools, and coach manual with coaching cards. These tools
will be presented and outcomes impacting length of orientation,
retention, coach satisfaction, and new nurse satisfaction will be
detailed.
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SAFETY OF LEUKAPHERESIS IN DONORS AND PATIENTS WITH WBC
COUNTS GREATER THAN 60K
Drago, S.S. Duke University Medical Center, Durham, NC.
As new protocols are developed and treatment plans change, the
demand for higher numbers of donor stem cells for patients has
increased. This is especially true for non-myeloablative transplants
where a higher cell dose may be needed to assure engraftment.
There is a concern for safety in this donor population that elevated
white blood cell counts may lead to altered blood ﬂow kinetics,
cause shortness of breath, decreased cerebral blood ﬂow, and con-
tribute to cardiac ischemia.
In reviewing 3037 leukapheresis collections in Duke University
adult bone marrow stem cell transplant program over a 7-year
period, it was noted that pre-leukapheresis WBC counts were
greater than or equal to 60,000/microliter in 296 cases (9.75%). A
WBC count greater than or equal to 100,000 was noted in 7 cases
(0.23%).
In reviewing our apheresis records for patients with WBC
greater than 60,000/microliter, there were no serious adverse
events reported other than the common reports of myalgia, bone
pain, and headache associated with administration of cytokine.
Pain levels ranged from mild to severe. Pain was managed in most
cases by either over the counter analgesics and some required a
mild narcotic.
Our apheresis SOP directs nursing staff to contact the physician
when the pre-leukapheresis WBC is greater than 60,000/mcl. The
physician reviews the cytokine dose and the numbers of cells
collected and provides the apheresis nurse with orders for with-
holding a dose of cytokine or for a 50% dose reduction. The
circulating CD-34 count does not consistently correlate to the
elevated WBC and can drop rapidly when cytokines are withheld
which may be problematic if the target number of cells for trans-
plantation has not been reached. Careful nursing and physician
assessment and monitoring for adverse events in this donor pop-
ulation include pain levels, breathing difﬁculties, chest discomfort
and any neurological changes. After careful evaluation of the data,
we feel collections of CD-34 cell from donors and patients with
WBC greater than 60,000 can be safely performed (Table1).
Table 1. WBC vs CD-34










60-69 40 64.6 81.6 60 63.8 110.0 100
70-79 30 74.3 89.5 16 74.5 95.2 46
80-89 13 84.1 56.9 5 85.7 84.1 18
90-99 6 94 95.5 5 94.1 105.1 11
100 4 110.5 318.3 3 102.7 68.9 7
total 93 74.3 91.8 89 70.0 104.3 182
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THE NURSING ROLE IN THE ORIENTATION AND EDUCATION FOR
OUTPATIENT PRE-HSCT PATIENTS, FAMILIES, AND CAREGIVERS AT
THE SEATTLE CANCER CARE ALLIANCE
Buzy-Hummel, A.M. Seattle Cancer Care Alliance, Seattle, WA.
When patients, families, and caregivers arrive at the Seattle
Cancer Care Alliance in preparation for a Hemopoietic Stem Cell
Transplant, they are often overwhelmed with information and
clinic appointments. The HSCT clinic nurses play a pivotal role in
orienting and educating patients and caregivers as they are evalu-
ated for transplant. To ensure consistent education, a comprehen-
sive process of clinic visits, written education materials, and classes
was developed to support patients and caregivers through the ﬁrst
several weeks in the Outpatient Clinic. The nursing process and
clinics are supported by written policies and procedures that out-
line nursing responsibilities. The proposed poster will communi-
cate the SCCA nursing role in the pre transplant orientation and
education of patients, family and caregivers.
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ESTABLISHMENT OF A LONG-TERM ALLOGENEIC BLOOD AND MAR-
ROW FOLLOW-UP PROGRAM FOR EARLY DETECTION OF COMPLICA-
TIONS AND MEASURING OUTCOMES
Neumann, J.L., Trevino, C.M., Hsu, Y., Popat, U., Champlin, R.E.,
Couriel, D. The University of Texas M. D. Anderson Cancer Center,
Houston, TX.
Almost 60% of the 613 patients transplanted at our center last
year received allogeneic blood or marrow transplantation. Alloge-
neic BMT complications are most prevalent in the ﬁrst 100 days,
but late infections and chronic graft versus host disease frequently
occur after patients leave our comprehensive cancer center at day
100. Establishing a thorough, comprehensive and central computer
accessible patient assessment will enable practitioners to phone
triage problems with community healthcare providers and identify
changes during follow-up visits for prevention, early detection of
complication, and prompt referrals. At our center the patient’s
initial BMT physician remains involved in the care throughout the
transplant process and follow-up. Referrals to our GVHD clinic
occur as deemed appropriate by the clinic physician. Capture of the
overall program incidence and severity of complications like
GVHD can be problematic. We have assigned one full-time Nurse
Practitioner (NP) to follow the allogeneic patients from day 80-
100 to the end of the ﬁrst year after transplantation. The LTFU
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program NP coordinates care with the patient’s clinic physician
and Physician Assistant (PA). An extensive assessment is performed
around the time the patient will be leaving the transplant center.
Baseline data and outcome tracking will include incidence and
severity of chronic graft vs host disease, infections, endocrine and
nutritional disorders, quality of life, and survival. Information
about assessment tools and outcomes will be shared, as well as a
case study.
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IMPROVING CLINICAL OUTCOMES UTILIZING A BMT UNIT-BASED
CLINICAL PRACTICE COUNCIL
Adlard, K., Patterson, M. Children’s Hospital of Orange County, Or-
ange, CA.
A BMT unit-based Clinical Practice Council (CPC) was formed
in our Oncology Intensive Care Unit (OICU) to address clinical
issues and improve clinical outcomes for our pediatric BMT pa-
tients. The nurses in the OICU were concerned about several
patient care issues and inconsistent clinical practice. Due to the
nursing shortage, our unit is often staffed with new graduate
nurses, registry and traveling nurses, and nurses ﬂoating from
other units, which often results in inconsistent clinical practice. In
order to address the clinical issues and increase staff involvement,
the Clinical Director and Clinical Nurse Specialist (CNS) devel-
oped a unit-based Clinical Practice Council. The Clinical Practice
Council consists of the Charge Nurses, staff nurses from both
shifts, the BMT Coordinators, the Clinical Director, and the CNS.
At our ﬁrst meeting, the nurses were asked to brainstorm about the
clinical issues that they were concerned about and then prioritize
the issues. All Clinical Practice Council members were asked to
“volunteer” for one or more clinical issues that they would like to
research and determine best practices. The staff embraced the
challenge and went straight to work. The nurses have worked on a
variety of issues that have resulted in practice changes and im-
proved clinical outcomes. For example, we have made improve-
ments in our BMT diet, calorie counts, blood specimen collection
from central venous catheters, documentation of ﬂuid balance,
discharge education, and blood product utilization. Recommenda-
tions for clinical practice changes are presented to the BMT Med-
ical Director, Oncologists, and other disciplines as needed for
review and approval. The Clinical Practice Council has been suc-
cessful in improving clinical outcomes, increasing staff involve-
ment and job satisfaction, and increasing patient and family satis-
faction. Based on the success of this practice council model in the
OICU, we have implemented Clinical Practice Councils in our
Cancer Institute Clinic and Hematology/Oncology Unit.
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ARSENIC TRIOXIDE IN COMBINATION WITH ASCORBIC ACID AND
HIGH-DOSE MELPHALAN IS SAFE FOR PATIENT WITH MM UNDERGO-
ING AN AUTOLOGOUS TRANSPLANT
Libunao, F.R., Roden, L.X., Davis, M.S., Champlin, R., Giralt, S.,
Qazilbash, M. The University of Texas M. D. Anderson Cancer Center,
Houston, TX.
Purpose: To evaluate the safety of a new conditioning regimen
of arsenic trioxide (ATO), ascorbic acid (AA), and Melphalan for
patient with multiple myeloma undergoing an autologous hema-
topoietic stem cell transplantation. Rationale: ATO is an active
agent against multiple myeloma and has been shown to have
synergistic effect with melphalan and ascorbic acid AA both in vitro
and in vivo.Design: Phase I/II clinical trialMethods: Twenty-ﬁve
patients with multiple myeloma (11 females, 14 males median age:
53, range: 49-69) were treated between 4/04 and 1/05. All patient
received melphalan 100 mg/m2 IV on days 4 and 3 and AA
1000 mg/day IV on days 9 to 3. Patients were randomized to 3
arms; no ATO (arm 1), ATO 0.15 mg/kg IV on days 9 to 3
(arm 2) and ATO 0.25 mg/kg IV on days 9 to 3 (arm 3). Seven
patients had a prior autograft. Median CD34 cells dose infused was
4.4  106/kg (range 2.3-10.9). Results: With a median F/U of 7.1
months post autograft, no dose-limiting toxicity or non-relapse
mortality was seen. Median ATO level on day 0 in arms 1, 2, and
3 were 0.2, 26.3 and 46.2 ng/ml, respectively. Median time to
neutrophil engraftment (ANC 	500/ dl) was 9 days. There were
no engraftment failures or delays in the ATO arms. Toxicity was
limited grade I or II nausea, vomiting and diarrhea. See Table 1.
Conclusions: Arsenic trioxide given in combination with melpha-
lan and ascorbic acid as preparative regimen for an autograft is safe
and well tolerated. No dose limiting toxicity or adverse effects or
delays in engraftment were seen. No difference in infections was
noted at any dose level (Table1).
Table 1. Toxicities
Patient
no. Dose Level Toxicities Day 0 Toxicities Day 15
Toxicities
Day 30
1 placebo none none none
2 .15mg/kg/day N&V gr 1 none none
3 placebo N & V gr 1 N & V gr 1, dia
gr 1, muco gr 2
none
4 .25mg/kg/day none N & V gr 1 none
5 .15mg/kg/day N & V gr 1, mucogr
1, diarr gr 1,
perip edema gr 1
none none
6 .15mg/kg/day N & V gr 1, diarr gr
1
none none
7 .15mg/kg/day N & V gr 1, diarr gr
1, fever gr 1
none none
8 .15mg/kg/day N & V gr 1, fever gr
1
diarr gr 1 none
9 .15mg/kg/day diarr gr 1, mucos gr
1, pedal edema gr
1, N & V gr 1
none none
10 .15mg/kg/day hypert gr 1, neu fev
gr 1
N & V gr 1, ALT,
AST gr 1,
creatgr 1, GI &
chest pain gr 1
none
11 .15mg/kg/day none none none
12 .15mg/kg/day N & V gr 1, diarr gr
1, mucos gr 1
none N & V gr 1
13 .15mg/kg/day N & V gr 1 none none
14 .15mg/kg/day perip edema gr 1,
diarr gr 1
N & V gr 1 none
15 .15mg/kg/day nausea gr 1 perip edema gr 1 none
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ADVERSE EVENTS TO CAMPATH IN A PEDIATRIC SETTING
Klinger, E.F., Daum, C.D., Neudorf, S.M.L., Snyder, R., Simpson, L.M.
Children’s Hospital of Orange County (CHOC), Orange, CA.
Alemtuzumab (Campath) has been used to prevent graft versus
host disease in adult recipients of unrelated donor bone marrow.
Given the limited experience using Campath in pediatrics, we are
reporting the incidence of adverse reactions.
Campath (0.2 mg/kg/day IV  5 days) was given to recipients on
day 8 or 9 prior to receiving grafts from a HLA matched unrelated
donor. All patients received Acetaminophen (10-15 mg/kg/dose
PO, 650 mg max) and Diphenhydramine (1mg/kg/dose PO/IV) to
prevent adverse reactions. Adverse events were identiﬁed from the
retrospective review of nursing and physician progress notes. Re-
sults: 10 patients received Campath. All 10 patients had reactions
to Campath including fever (n  7), chills (n  3), hypotension
(n 2), urticaria (n 1), anxiety (n 1), headache (n 1), nausea
and emesis (n  1). Four patients received IVIG during their
preparative therapy. Given the high incidence of adverse reactions
despite premedication, the program adapted the following practice
changes: (1) BMT order sets were revised to encompass immediate
intervention algorithm for wider range of adverse reactions. The
algorithm calls for a stop of infusion, drug intervention(s), and
physician notiﬁcation. If SOB develops, Hydrocortisone (1-2 mg/
kg/dose IV, 100 mg max) will be given, NS bolus (10-20 mg/kg/
dose, 1000 ml max) will be added for hypotension, Meperidine (1
mg/kg/dose IV, 50mg max) for rigors and Ranitidine (1-2 mg/kg/
dose IV, 50 mg max) for rash. (2) Campath administration is
scheduled in the day shift in order to facilitate close monitoring
and medical staff availability. (3) IVIG will be given either prior to
start of conditioning or at day 1. (4) The program will collect
prospect data to evaluate the efﬁcacy of the practice change.
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